Final progression-free survival analysis of BOLERO-2: a phase Ill trial of everolimus for postmenopausal women with advanced breast cancer

被引：3
|
作者：
Piccart, M.
Baselga, J.
Noguchi, S.
Burris, H.
Gnant, M.
Hortobagyi, G.
Mukhopadhyay, P.
Taran, T.
Sahmoud, T.
Rugo, H.
机构：
[1] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium
[2] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[3] Harvard Univ, Sch Med, Boston, MA USA
[4] Osaka Univ, Osaka, Japan
[5] Sarah Cannon Res Inst, Nashville, TN USA
[6] Med Univ Vienna, Ctr Comprehens Canc, Vienna, Austria
[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[8] Novartis Pharmaceut, E Hanover, NJ USA
[9] Univ Calif San Francisco, San Francisco Helen Diller Family Comprehens Canc, San Francisco, CA 94143 USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/0008-5472.SABCS12-126-04-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-04-02
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Progression-free survival is a surrogate of survival in maintenance therapy for metastatic breast cancer: Randomized trial level analysis
    Song, E.
    Yao, H.
    Yu, Y.
    Ou, Q.
    Wang, Y.
    CANCER RESEARCH, 2019, 79 (04)
  • [42] BOLERO-2: Efficacy, safety, and quality of life in patients with advanced breast cancer receiving first-line everolimus plus exemestane
    Campone, M.
    Lebrun, F.
    Neven, P.
    Pistilli, B.
    Rugo, H.
    Baselga, J.
    Brechenmacher, T.
    Taran, T.
    Sahmoud, T.
    Hortobagyi, G.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S419 - S420
  • [43] Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial
    Burris, Howard A., III
    Lebrun, Fabienne
    Rugo, Hope S.
    Beck, J. Thaddeus
    Piccart, Martine
    Neven, Patrick
    Baselga, Jose
    Petrakova, Katarina
    Hortobagyi, Gabriel N.
    Komorowski, Anna
    Chouinard, Edmond
    Young, Robyn
    Gnant, Michael
    Pritchard, Kathleen I.
    Bennett, Lee
    Ricci, Jean-Francois
    Bauly, Hounayda
    Taran, Tetiana
    Sahmoud, Tarek
    Noguchi, Shinzaburo
    CANCER, 2013, 119 (10) : 1908 - 1915
  • [44] Influence of clinical trial participation with regard to overall survival (OS) and progression-free survival (PFS) for patients with advanced breast cancer
    Kiechle, M.
    Simstich, N. S.
    Schwarz-Boeger, U. R.
    Paepke, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [45] Assessment of genetic alterations using next-generation sequencing in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the BOLERO-2 phase III trial
    Baselga, Jose
    Piccart, Martine
    Rugo, Hope
    Chen, David
    Burris, Howard A.
    Campone, Mario
    Noguchi, Shinzaburo
    Perez, Alejandra
    Deleu, Inas
    Shtivelband, Mikhail
    Provencher, Louise
    Derti, Adnan
    Huang, Alan
    McDonald, Rob
    Kalfoglou, Creton
    Robinson, Douglas
    Taran, Tetiana
    Sahmoud, Tarek
    Lebwohl, David
    Hortobagyi, Gabriel N.
    CANCER RESEARCH, 2013, 73 (08)
  • [46] Dalpiciclib Extends Progression-Free Survival in HR+/HER2-Advanced Breast Cancer
    不详
    ONCOLOGIST, 2021, 26 : S9 - S10
  • [47] Predicting Overall Survival and Progression-Free Survival Using Tumor Dynamics in Advanced Breast Cancer Patients
    Hyeong-Seok Lim
    Wan Sun
    Kourosh Parivar
    Diane Wang
    The AAPS Journal, 21
  • [48] Predicting Overall Survival and Progression-Free Survival Using Tumor Dynamics in Advanced Breast Cancer Patients
    Lim, Hyeong-Seok
    Sun, Wan
    Parivar, Kourosh
    Wang, Diane
    AAPS JOURNAL, 2019, 21 (02):
  • [49] Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON)
    Shinzaburo Noguchi
    Matthew J. Ellis
    John F. R. Robertson
    Jackie Thirlwell
    Mehdi Fazal
    Zhimin Shao
    Breast Cancer, 2018, 25 : 356 - 364
  • [50] Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON)
    Noguchi, Shinzaburo
    Ellis, Matthew J.
    Robertson, John F. R.
    Thirlwell, Jackie
    Fazal, Mehdi
    Shao, Zhimin
    BREAST CANCER, 2018, 25 (03) : 356 - 364
12345